Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D. Leverson, Andrew J. Souers, Dolores Diaz et al.|Science Translational Medicine|2015Cited by 541
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancerEmily J. Faivre, Yu Shen, Keith F. McDaniel et al.|Nature|2020Cited by 404